The @entity1701 ( @entity1701 ) is defined by the presence of antiphospholipid antibodies (aPLs) with venous or arterial @entity715 , recurrent @entity393 or @entity882 . The syndrome can be either primary or secondary to an underlying condition, most commonly @entity1252 ( @entity1252 ). The purpose of the study was to review the manifestations of the @entity1701 in Israeli @entity1 and to investigate the difference between @entity1 with primary or secondary syndrome. Analysis of the correlation between the manifestations of the disease and the antibody titers [ @entity4555 ( @entity4555 ), IgG aCL (anticardiolipin), IgM aCL] was also performed. In the study there were 90 @entity1 with @entity1701 in the Sheba Medical Center. The clinical findings for all @entity1 were recorded according to established protocol. RESULTS: Arterial @entity715 events were present in 51.1% of the @entity1 ; cerebral ischemic attacks were the most frequent arterial events. @entity49 events were present in 45.6% @entity1 ; @entity1150 was the most frequent venous event. Obstetric complications were found in 37.3% of @entity1 ; the most frequent complication was abortions. The clinical findings of @entity1 with primary or secondary syndrome were similar. @entity1 with @entity1701 associated with lupus had a high prevalence of @entity5714 (28.6% v 3.3%; P = 0.001), and ANA (antinuclear antibody) (75% v 12.9%; P = 0.0001). There was no correlation between the antibody titers ( @entity4555 , IgG aCL, IgM aCL) and clinical manifestations. The patients received anticoagulant treatment and antiaggregant drugs to prevent recurrence of symptoms. Clinical manifestations in Israeli @entity1 did not differ from those in non-Israeli @entity1 . CONCLUSIONS: @entity455 are the most frequent clinical findings in @entity1701 . There was no different in clinical manifestations between primary and secondary syndrome. The findings of @entity5506 and ANA were more frequent in @entity1 with secondary @entity1701 . There was no correlation between antiphospholipid antibody titers and manifestations of disease. Overall, the @entity1 require therapy with anticoagulant treatment and antiaggregant drugs. The clinical manifestations were similar in Israeli and non-Israeli @entity1 .

[Following 90 patients with XXXX with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['Venous or arterial thrombosis and obstetric complications'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity49 :: ('MESH:D019851', 'Disease') :: ['Venous thrombotic'] @entity1701 :: ('MESH:D016736', 'Disease') :: ['APS', 'antiphospholipid syndrome'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis'] @entity5506 :: ('MESH:D000744', 'Disease') :: ['autoimmune hemolytic anemia'] @entity4555 :: ('MESH:C531622', 'Disease') :: ['lupus anticoagulant', 'LA'] @entity5714 :: ('MESH:D000743', 'Disease') :: ['hemolytic anemia'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic'] @entity393 :: ('MESH:D034381', 'Disease') :: ['pregnancy loss']
@entity1701 :: (MESH:D016736,Disease) :: ['antiphospholipid syndrome']
